{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:50:03Z","timestamp":1791474603689,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":1306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1093\/annonc\/mdw004","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T02:31:34Z","timestamp":1453516294000},"page":"680-687","source":"Crossref","is-referenced-by-count":48,"title":["A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"27","author":[{"given":"T.","family":"Ciuleanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lungulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deptala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodriguez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Giantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Kalyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw004_bb0010","series-title":"GLOBOCAN: estimated cancer incidence, mortality and prevalence worldwide in 2012","author":"World Health Organisation","year":"2012"},{"key":"10.1093\/annonc\/mdw004_bb0015","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw004_bb0020","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.3748\/wjg.14.4300","article-title":"Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis","volume":"14","author":"Gomaa","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1093\/annonc\/mdw004_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: the BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1093\/annonc\/mdw004_bb0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1093\/annonc\/mdw004_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdw004_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw004_bb0045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2003.12.008","article-title":"A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases","volume":"9","author":"Sova","year":"2004","journal-title":"Mol Ther"},{"key":"10.1093\/annonc\/mdw004_bb0050","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","article-title":"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo","volume":"92","author":"Pukac","year":"2005","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"10.1093\/annonc\/mdw004_bb0055","article-title":"The TRAIL receptor 1 antibody, mapatumumab, synergizes with cisplatin or doxorubicin to enhance anti-tumor activity in hepatocellular carcinoma","volume":"98","author":"Humphreys","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4020-6554-5_7","article-title":"Trail receptors: targets for cancer therapy","volume":"615","author":"Humphreys","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1093\/annonc\/mdw004_bb0065","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1200\/JCO.2006.08.8898","article-title":"Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1","volume":"25","author":"Tolcher","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0070","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/1078-0432.CCR-07-1416","article-title":"A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies","volume":"14","author":"Hotte","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2007.12.011","article-title":"Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer","volume":"61","author":"Greco","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdw004_bb0080","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2008.21.7422","article-title":"Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study","volume":"27","author":"Leong","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0085","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-09-0996","article-title":"Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study","volume":"15","author":"Mom","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0090","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.bjc.6605987","article-title":"A phase 1b\/2 trial of mapatumumab in patients with relapsed\/refractory non-Hodgkin's lymphoma","volume":"103","author":"Younes","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw004_bb0095","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/sj.bjc.6605507","article-title":"Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer","volume":"102","author":"Trarbach","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw004_bb0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2013.12.005","article-title":"Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"15","author":"von Pawel","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"suppl 4","key":"10.1093\/annonc\/mdw004_bb0105","article-title":"Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis","volume":"29","author":"Sun","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0110","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-05-0808","article-title":"The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells","volume":"66","author":"Panka","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0115","doi-asserted-by":"crossref","first-page":"35217","DOI":"10.1074\/jbc.M506551200","article-title":"Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation","volume":"280","author":"Rahmani","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdw004_bb0120","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdw004_bb0130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdw004_bb0135","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.3748\/wjg.15.5924","article-title":"TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies","volume":"15","author":"Koehler","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1093\/annonc\/mdw004_bb0140","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/1078-0432.CCR-09-3389","article-title":"Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3","volume":"16","author":"Chen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0145","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-09-1004","article-title":"Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells","volume":"9","author":"Huang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdw004_bb0150","doi-asserted-by":"crossref","first-page":"29831","DOI":"10.1074\/jbc.M706110200","article-title":"Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization","volume":"282","author":"Meng","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdw004_bb0155","doi-asserted-by":"crossref","first-page":"e75414","DOI":"10.1371\/journal.pone.0075414","article-title":"Sorafenib sensitizes solid tumors to Apo2L\/TRAIL and Apo2L\/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis","volume":"8","author":"Abdulghani","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw004_bb0160","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw004_bb0165","first-page":"25691","article-title":"Guideline for good clinical practice E6(R1)","volume":"62","author":"ICH Harmonised Tripartite Guideline","year":"1996","journal-title":"Federal Register"},{"key":"10.1093\/annonc\/mdw004_bb0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"issue":"2 Suppl 1","key":"10.1093\/annonc\/mdw004_bb0175","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/lt.20034","article-title":"The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma","volume":"10","author":"Llovet","year":"2004","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1093\/annonc\/mdw004_bb0180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1093\/annonc\/mdw004_bb0190","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw004_bb0195","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1872-034X.2009.00568.x","article-title":"Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis","volume":"39","author":"Zhang","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1093\/annonc\/mdw004_bb0200","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1369\/jhc.3A6112.2004","article-title":"Tissue distribution of the death ligand TRAIL and its receptors","volume":"52","author":"Spierings","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"10.1093\/annonc\/mdw004_bb0205","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1158\/1078-0432.CCR-09-3403","article-title":"Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma","volume":"16","author":"Kriegl","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw004_bb0210","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0215","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw004_bb0225","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/4\/680\/16700195\/mdw004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:01:29Z","timestamp":1624694489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419357552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0923753419357552"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw004","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}